| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
m-PEG4-bromide does not target a biological receptor. Its function is as a chemical linker. The bromide group (-Br) is the key reactive moiety. It is an excellent leaving group that can be displaced by a nucleophile, such as an amine, thiol, or alkoxide, in an SN2 reaction. This allows for the introduction of various functional groups at the terminus of the PEG chain. In the context of ADCs, it serves as a linker to connect the antibody to the cytotoxic payload.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
As a chemical linker, m-PEG4-bromide has no intrinsic biological activity. Its utility is derived from its chemical reactivity. The bromide group provides a site for nucleophilic substitution, allowing for the attachment of a wide variety of molecules. The short PEG4 spacer provides a balance between hydrophilicity and compactness. The compound is classified as a cleavable ADC linker, meaning it is designed to be cleaved under specific conditions to release the payload. |
| ln Vivo |
No direct in vivo activity is attributed to m-PEG4-bromide itself. Its role is as a component in larger therapeutic constructs. In ADCs, the PEG4 linker connects the antibody to the cytotoxic drug, helping to improve the drug's solubility and stability in circulation.
|
| Enzyme Assay |
For in vitro characterization, m-PEG4-bromide is typically analyzed by NMR and HPLC to confirm its structure and purity. Purity is often ≥95% to 98%. The bromide content can be quantified by elemental analysis or by titration. Its solubility in various solvents is determined.
|
| Cell Assay |
Cell-based assays are not performed on m-PEG4-bromide itself. As a linker, it is incorporated into larger constructs (ADCs) that are then evaluated in cell culture. For example, an ADC containing the m-PEG4-bromide linker would be tested for its ability to bind to cancer cells, be internalized, and deliver a cytotoxic payload.
|
| Animal Protocol |
In vivo studies with m-PEG4-bromide are conducted using the final conjugate (ADC). These studies typically involve administering the conjugate to animal models to assess its pharmacokinetics, efficacy, and safety. The PEG4 spacer contributes to the overall performance of the conjugate.
|
| ADME/Pharmacokinetics |
As a linker, m-PEG4-bromide does not have independent pharmacokinetic (PK) properties. However, the PEG4 spacer can improve the aqueous solubility of the final conjugate.
|
| Toxicity/Toxicokinetics |
The toxicology of m-PEG4-bromide is not typically evaluated independently. PEG is generally considered to be biocompatible and non-toxic. The bromide group is a reactive alkylating agent and may be irritating, but it is typically consumed during the conjugation process.
|
| References |
[1]. Walker JA, et al. Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates.Bioconjug Chem. 2019 Nov 20;30(11):2982-2988.
|
| Additional Infomation |
m-PEG4-bromide is a monodisperse, heterobifunctional PEG derivative with a bromide group, used as a cleavable ADC linker. It has a molecular weight of 271.15 g/mol and is a versatile intermediate for introducing various functional groups. The compound is available for research use only.
|
| Molecular Formula |
C9H19BRO4
|
|---|---|
| Molecular Weight |
271.1488
|
| Exact Mass |
270.047
|
| CAS # |
110429-45-3
|
| PubChem CID |
19389132
|
| Appearance |
Colorless to light yellow liquid（Density：1.256 g/cm3）
|
| Density |
1.256g/cm3
|
| Boiling Point |
296.3ºC at 760 mmHg
|
| Flash Point |
118.8ºC
|
| Vapour Pressure |
0.00256mmHg at 25°C
|
| Index of Refraction |
1.454
|
| LogP |
1.077
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
14
|
| Complexity |
103
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])[H]
|
| InChi Key |
YFFFQGXWMHAJPP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H19BrO4/c1-11-4-5-13-8-9-14-7-6-12-3-2-10/h2-9H2,1H3
|
| Chemical Name |
1-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]-2-methoxyethane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6880 mL | 18.4400 mL | 36.8800 mL | |
| 5 mM | 0.7376 mL | 3.6880 mL | 7.3760 mL | |
| 10 mM | 0.3688 mL | 1.8440 mL | 3.6880 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
